基于分子对接和QSAR方法预测B-Raf II型抑制剂活性

doi:10.3866/PKU.WHXB201510134

摘要/Abstract

摘要：

B-Raf激酶在促分裂素原活化蛋白激酶(MAPK)信号转导通路中起着重要作用,已被确定为癌症治疗非常有吸引力的靶标.新型高效B-Raf抑制剂的开发成为癌症治疗的一个热门研究领域.本文以结构多样的B-Raf II型抑制剂为研究对象,联合应用分子对接和定量构效关系(QSAR)模型研究其定量构效关系去探讨抑制活性的起源.两个主题作为研究重点:生物活性构象和描述符.首先对分子对接方法(Glide、Gold、LigandFit、Cdocker和Libdock)进行准确性评价,后将研究的对象分子对接到B-Raf活性位点并获得生物活性构象.基于准确的对接结果,计算得到16个打分评价函数和21个能量描述符,以此构建定量构效关系模型. QSAR结果表明模型具有高度精确的拟合和强的预测能力(模型M1: r² = 0.852, r_(CV)² = 0.790, r_pre² = 0.864;模型M2: r² = 0.738, r_(CV)² = 0.812, r_pre² = 0.8605).同时探讨了对抑制活性有重要影响的描述符,结果表明打分评价函数(G_Score, -ECD, Dock_Score, PMF)与能量描述符(S(hb_ext), DE(int), Emodel)对抑制活性影响非常大.通过虚拟筛选和QSAR模型理论预测,一些新的具有潜在抑制活性的化合物作为B-Raf II型抑制剂被获得.上述信息对于进一步设计新颖高效的B-Raf II型抑制剂提供了有用的指导.

关键词: B-Raf II型抑制剂, 分子对接, 打分评价函数, 对接能量描述符, 定量构效关系模型

Abstract:

B-Raf kinase plays an important role in the mitogen-activated protein kinase (MAPK) signaling transmission pathway and has been identified as an attractive target for cancer therapy. The exploitation of novel and efficient B-Raf inhibitors has become a hot research topic. In this study, we investigated quantitative structure-activity relationship (QSAR) to probe the origins of the inhibitory activities of B-Raf Type II inhibitors. We used structurally diverse B-Raf Type II inhibitors and an integrated docking and QSAR extended method. We focused mainly on two themes: bioactive conformations and descriptors. First, various molecular docking methods (Glide, Gold, LigandFit, Cdocker, and Libdock) were evaluated, and then all molecules were docked into the B-Raf active site to obtain the bioactive conformations. Secondly, based on the docking results, 16 scoring functions and 21 docking-generated energy-based descriptors were calculated to construct regression models. The results gave highly accurate fitting and had strong predictive abilities (M1: r² = 0.852, r_(CV)² = 0.790, r_pre² = 0.864; M2: r² = 0.738, r_(CV)² = 0.812, r_pre² = 0.8605). The important descriptors were also explored to elucidate the main factors influencing the inhibition activities. The models suggested that the scoring functions (G_Score, -ECD, Dock_Score, and PMF) and docking-generated energy-based descriptors (S(hb_ext), DE(int), and Emodel) were significant. Some new compounds that are potential B-Raf inhibitors were obtained through virtual screening and theoretical predictions using the established models. Such information is useful in guiding the design of novel and robust B-Raf Type II inhibitors.

Key words: B-Raf Type II inhibitor, Molecular docking, Scoring function, Docking-generated energybased descriptor, Quantitative structure-activity relationship model

MSC2000:

O641

刘海春,卢帅,冉挺,张艳敏,徐金星,熊潇,徐安阳,陆涛,陈亚东. 基于分子对接和QSAR方法预测B-Raf II型抑制剂活性[J]. 物理化学学报, 2015, 31(11): 2191-2206.

Hai-Chun. LIU,Shuai. LU,Ting. RAN,Yan-Min. ZHANG,Jin-Xing. XU,Xiao. XIONG,An-Yang. XU,Tao. LU,Ya-Dong. CHEN. Accurate Activity Predictions of B-Raf Type II Inhibitors via Molecular Docking and QSAR Methods[J]. Acta Phys. -Chim. Sin., 2015, 31(11): 2191-2206.

参考文献

1	PeyssonnauxC.; EycheneA.. Biol. Cell, 2001, 93, 53.
2	Davies H. ; Bignell G. R. ; Cox C. ; Stephens P. ; Edkins S. ; Clegg S. ; Teague J. ; Woffendin H. ; Garnett M. J. ; Bottomley W. ; Davis N. ; Dicks E. ; Ewing R. ; Floyd Y. ; Gray K. ; Hall S. ; Hawes R. ; Hughes J. ; Kosmidou V. ; Menzies A. ; Mould C. ; Parker A. ; Stevens C. ; Watt S. ; Hooper S. ; Wilson R. ; Jayatilake H. ; Gusterson B. A. ; Cooper C. ; Shipley J. ; Hargrave D. ; Pritchard-Jones K. ; Maitland N. ; Chenevix-Trench G. ; Riggins G. J. ; Bigner D. D. ; Palmieri G. ; Cossu A. ; Flanagan A. ; Nicholson A. ; Ho J. W. C. ; Leung S. Y. ; Yuen S. T. ; Weber B. L. ; Seigler H. F. ; Darrow T. L. ; Paterson H. ; Marais R. ; Marshall C. J. ; Wooster R. ; Stratton M. R. ; Futreal P. A. Nature 2002, 417, 949.
3	Wan P. T. ; Garnett M. J. ; Roe S. M. ; Lee S. ; Niculescu-Duvaz D. ; Good V. M. ; Jones C. M. ; Marshall C. J. ; Springer C. J. ; Barford D. ; Marais R. Cell 2004, 116, 855.
4	Samowitz W. S. ; Sweeney C. ; Herrick J. ; Albertsen H. ; Levin T. R. ; Murtaugh M. A. ; Wolff R. K. ; Slattery M. L. Cancer Res 2005, 65, 6063.
5	Riesco-Eizaguirre G. ; Gutiérrez-Martínez P. ; García-Cabezas M. A. ; Nistal M. ; Santisteban P. Endocr-Relat. Cancer 2006, 13, 257.
6	Wang X. ; Kim J. J. Med. Chem 2012, 55 (17), 7332.
7	Wilhelm S. M. ; Carter C. ; Tang L. ; Wilkie D. ; McNabola A. ; Rong H. ; Chen C. ; Zhang X. ; Vincent P. ; McHugh M. ; Cao Y. ; Shujath J. ; Gawlak S. ; Eveleigh D. ; Rowley B. ; Liu L. ; Adnane L. ; Lynch M. ; Auclair D. ; Taylor I. ; Gedrich R. ; Voznesensky A. ; Riedl B. ; Post L. E. ; Bollag G. ; Trail P. A. Cancer Res 2004, 64, 7099.
8	Wilhelm S. ; Carter C. ; Lynch M. ; Lowinger T. ; Dumas J. ; Smith R. A. ; Schwartz B. ; Simantov R. ; Kelley S. Nat. Rev. Drug Discov 2006, 5 (10), 835.
9	Wilhelm S. M. ; Dumas J. ; Adnane L. ; Lynch M. ; Carter C. A. ; Schütz G. ; Thierauch K. H. ; Zopf D. Int. J. Cancer 2011, 129 (1), 245.
10	Strumberg D. ; Schultheis B. Expert Opin. Investig. Drugs 2012, 21 (6), 879.
11	Chapman P. B. ; Hauschild A. ; Robert C. ; Haanen J. B. ; Ascierto P. ; Larkin J. ; Dummer R. ; Garbe C. ; Testori A. ; Maio M. ; Hogg D. ; Lorigan P. ; Lebbe C. ; Jouary T. ; Schadendorf D. ; Ribas A. ; O'Day S. J. ; Sosman J. A. ; Kirkwood J. M. ; Eggermont A. M. M. ; Dreno B. ; Nolop K. ; Li J. ; Nelson B. ; Hou J. ; Lee R. J. ; Flaherty K. T. ; McArthur G. A. N. Engl. J. Med 2011, 364, 2507.
12	Bollag G. ; Tsai J. ; Zhang J. ; Zhang C. ; Ibrahim P. ; Nolop K. ; Hirth P. Nature. Rev. Drug. Discov 2012, 11, 873.
13	Rheault T. R. ; Stellwagen J. C. ; Adjabeng G. M. ; Hornberger K. R. ; Petro K. G. ; Waterson A. G. ; Dickerson S. H. ; Mook R. A. Jr. ; Laquerre S. G. ; King A. J. ; Rossanese O. W. ; Arnone M. R. ; Smitheman K. N. ; Kane-Carson L. S. ; Han C. ; Moorthy G. S. ; Moss K. G. ; Uehling D. E. ACS Med. Chem. Lett 2013, 4, 358.
14	Kim D. H. ; Sim T. Arch. Pharm. Res 2012, 35, 605.
15	Holderfield M. ; Deuker M. M. ; McCormick F. ; McMahon M. Nat. Rev. Cancer 2014, 14, 455.
16	Ackerman A. ; Klein O. ; McDermott D. F. ; Wang W. ; Ibrahim N. ; Lawrence D. P. ; Gunturi A. ; Flaherty K. T. ; Hodi F. S. ; Kefford R. ; Menzies A. M. ; Atkins M. B. ; Long G. V. ; Sullivan R. J. Cancer 2014, 120, 1695.
17	Hartsough E. ; Shao Y. ; Aplin A. E. J. Invest. Dermatol 2014, 134, 319.
18	Bucheit A. D. ; Davies M. A. Biochem. Pharmacol 2014, 87 (3), 381.
19	Zhang F. ; Lu T. ; Tang W. F. Prog. Pharm. Sci 2014, 38, 31.
19	张帆; 陆涛; 唐伟方. 药学进展, 2014, 38, 31.
20	Enyedy I. J. ; Egan W. J. J. Comput. Aided Mol. Des 2008, 22, 161.
21	Kroemer R. T. Curr. Protein Pept. Sci 2007, 8, 312.
22	Lin J. ; Li Z. G. ; Zou J. W. ; Lu S. Y. Acta Chim. Sin 2012, 11, 1309.
22	林军; 李祖光; 邹建卫; 陆绍永. 化学学报, 2012, 11, 1309.
23	Li X. D. ; Hou T. J. ; Xu X. J. Acta Phys. -Chim. Sin 2005, 21, 504.
23	李旭东; 侯廷军; 徐筱杰. 物理化学学报, 2005, 21, 504.
24	Li M. Y. ; Xia L. Journal of China Pharmaceutical University 2003, 34 (6), 586.
24	李敏勇; 夏霖. 中国药科大学学报, 2003, 34 (6), 586.
25	Patel H. M. ; Noolvi M. N. ; Sharma P. ; Jaiswal V. ; Bansal S. ; Lohan S. ; Kumar S. S. ; Abbot V. ; Dhiman S. ; Bhardwaj V. Med. Chem. Res 2014, 23, 4991.
26	Maestro, Version 9.0; Schrö dinger, L. L. C.: New York, 2011
27	GOLD, Version 4.0; Astex Technology: Cambridge, 2001
28	Discovery Studio Client, Version 2.5; Accelrys Inc.: San Diego, 2008
29	Chen L. ; Chen X. J. Mol. Graph. Model 2012, 33, 35.
30	Frączek T. ; Siwek A. ; Paneth P. J. Chem. Inf. Model 2013, 53, 3326.
31	SYBYL, Version 7.1; Tripos Inc.: St. Louis, Missouri, 63144, U. S. A.
32	Hassan M. ; Bielawski J. ; Hempel J. ; Waldman M. Mol. Divers 1996, 2 (1-2), 64.
33	Matter H. ; Potter T. J. Chem. Inf. Comput. Sci 1999, 39 (6), 1211.
34	TSAR Software, Version 3. 3; Accelrys Inc.: Oxford, England
35	Roy K. Expert Opin. Drug Discov 2007, 2, 1567.
36	Qin L. T. ; Liu S. S. ; Xiao Q. F. ; Wu Q. S. Environ. Chem 2013, 32, 1205.
36	覃礼堂; 刘树深; 肖乾芬; 吴庆生. 环境化学, 2013, 32, 1205.
37	Tropsha A. ; Gramatica P. ; Gombar V. K. QSAR Comb. Sci 2003, 22, 69.

[1]	邓迎春,柳青,黄强. 禽流感病毒HA蛋白与人受体的分子对接[J]. 物理化学学报, 2017, 33(3): 633 -641 .
[2]	邓玉玲,余璐,黄强. 人类蛋白激酶组的多靶点分子对接系统[J]. 物理化学学报, 2016, 32(9): 2355 -2363 .
[3]	徐诗文,林东强,姚善泾. 人血白蛋白结合位点Ⅱ的分子结合模式研究[J]. 物理化学学报, 2016, 32(7): 1819 -1828 .
[4]	林峰,付新梅,王超,蒋思宇,王景辉,张述伟,杨凌,李燕. 3C-like蛋白酶抑制剂的构效关系、分子对接和分子动力学[J]. 物理化学学报, 2016, 32(11): 2693 -2708 .
[5]	罗棋耀,王紫鋆,金宏威,刘振明,张亮仁. 分子对接打分修正及在内皮脂肪酶选择性抑制剂筛选中的应用[J]. 物理化学学报, 2016, 32(10): 2606 -2619 .
[6]	张淑贞,郑超,朱长进. 芳香噻嗪类衍生物作为选择性醛糖还原酶抑制剂的分子对接和基于受体的三维定量构效关系研究[J]. 物理化学学报, 2015, 31(12): 2395 -2404 .
[7]	康从民, 赵绪浩, 王新宇, 程家高, 吕英涛. 五元杂环并嘧啶类胸苷酸合成酶抑制剂的构效关系和分子对接[J]. 物理化学学报, 2013, 29(02): 431 -438 .
[8]	白姝, 周荣, 刘夫锋. 胰蛋白酶定向固定化亲和配基的理性设计[J]. 物理化学学报, 2013, 29(02): 439 -448 .
[9]	黄阳玉, 阳秀凤, 李昊田, 纪晓峰, 程洪礼, 赵蕴杰, 郭大川, 李林, 刘士勇. 蛋白质-RNA相互作用界面预测与设计[J]. 物理化学学报, 2012, 28(10): 2390 -2400 .
[10]	乔康, 曾凌晓, 金宏威, 刘振明, 张亮仁. 人类腺苷受体A₃亚型拮抗剂的构效关系分析[J]. 物理化学学报, 2012, 28(06): 1509 -1519 .
[11]	胡衍保, 彭静波, 顾硕, 裴剑锋, 邹忠梅. 复方心可舒治疗冠心病多靶点作用的分子对接[J]. 物理化学学报, 2012, 28(05): 1257 -1264 .
[12]	王存新, 常珊, 龚新奇, 杨峰, 李春华, 陈慰祖. 蛋白质-蛋白质分子对接中打分函数研究进展[J]. 物理化学学报, 2012, 28(04): 751 -758 .
[13]	申涛, 杜凤沛, 刘婷, 姚广伟, 吴峥, 方萌萌, 徐筱杰, 路慧哲, . 咪唑甘油磷酸酯脱水酶与含氮杂环磷酸酯类抑制剂作用方式的分子模拟[J]. 物理化学学报, 2011, 27(08): 1831 -1838 .
[14]	章媛, 陈亚东, 尤启冬, 邹丽云, 杨燕. 同源模建和分子对接研究HDAC1/HDAC8的选择性[J]. 物理化学学报, 2010, 26(06): 1676 -1686 .
[15]	郑春松, 徐筱杰, 刘献祥, 叶蕻芝. 精制透骨消痛颗粒防治骨性关节炎的计算机药理学[J]. 物理化学学报, 2010, 26(03): 775 -783 .